TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give informed consent~* Age \> 18 years~* HIV infection as confirmed by HIV-antibody test as per Kenyan guidelines~* CD4+ T-cell count ≤100 cells/µl~* Serum CrAg titer≥1:2~* Able to travel to district hubs (Sindo District Hospital, Lumumba Health Centre) for regular study visits~Exclusion Criteria:~* clinical meningitis:~* clinical sepsis:~* hemiparesis, aphasia, visual field deficit or other finding on neurological examination localizable to the central nervous system~* a history of culture proven or suspected (cryptococcal antigen present) cryptococcal meningitis~* a history of stroke or other infection of the central nervous system~* a seizure within the last 2 months~* currently taking or ever taken antiretroviral therapy~* currently taking anti-tuberculous therapy~* currently or recently (\<2 months) prescribed fluconazole, itraconazole, clotrimazole troches, amphotericin or other oral anti-fungal medications~* pregnant or breast-feeding~* alanine aminotransferase concentration more than 3 times the upper limit of normal~* neutrophil count \<1000x103 cells/mL~* hemoglobin \<8g/dL~* platelet count \<100,000x 103 platelets/mL~* creatinine clearance ≤50 ml/min~* individuals with active heavy alcohol use or active recreational drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5FC plus fluconazole (Type: EXPERIMENTAL): Combination therapy with oral fluconazole and flucytosine
- fluconazole alone (Type: ACTIVE_COMPARATOR): Fluconazole monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib In GvHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute skin, intestinal (histologically confirmed) or liver GvHD \> grade 1 according to standard criteria~2. Age ≥18 years~3. Failure of previous treatment, defined as presence of at least one of the following criteria:~   1. Treatment with prednisone/prednisolone/methylprednisolone in a dose of at least 2 mg/kg and lack of response after at least 7 days treatment~  2. Treatment with prednisone/prednisolone/methylprednisolone in a dose of at least 2 mg/kg and progression after at least 3 days of treatment~  3. Failure to taper the prednisone/prednisolone dose to \<0.6 mg/kg/day or methylprednisolone dose to \<0.5 mg/kg/day~4. Written informed consent~5. Ability to understand the nature of the study and the study related procedures and to comply with them~Exclusion Criteria:~1. Uncontrolled underlying disease~2. Active bleeding~3. Absence of clinical signs of acute GvHD~4. Diagnostic or distinctive clinical signs of chronic GvHD~5. Uncontrolled bacterial, viral or fungal infection~6. Absolute neutrophil count \<0.5x103/µl~7. Evidence of transplant-associated micrioangiopathy (TAM) (According to Jodele et al., 2015, diagnostic criteria for TAM)~8. Any previous JAK2 inhibitor treatment prior to study enrolment, except Ruxolitinib given prior to the allogeneic stem cell transplantation~9. Known Hypersensitivity to Ruxolitinib or any of the excipients~10. Known positivity for HIV, Hepatitis B or Hepatitis C at the time of screening.~11. Female patients who are pregnant or breast feeding~12. Concomitant use of any other investigational drug within the last thirty days before the start of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental intervention (Type: EXPERIMENTAL): Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
- Standard treatment (Type: ACTIVE_COMPARATOR): Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand the purpose and risks of the study and provide signed and dated informed consent.~* Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria).~* Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.~* Must satisfy the approved therapeutic indications for Tysabri as per Product Monograph.~* Must either be treatment naïve or have been treated with disease modifying therapy DMT(s) (such as, but not limited to, Avonex, Betaseron, Rebif, Copaxone, Extavia, Tecfidera and/or Gilenya) for ≤5 years total prior to date of informed consent.~* Decision to treat with Tysabri must precede enrollment.~Key Exclusion Criteria:~* Any prior treatment with Tysabri.~* Contraindications to treatment with Tysabri as described in the Product Monograph.~* History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.~* History of diagnosis of Primary Progressive Multiple Sclerosis \[PPMS\] and/or Secondary Progressive Multiple Sclerosis \[SPMS\].~* Receiving immunomodulatory or immunosuppressive therapy.~* Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).~* Immunocompromised at the time of enrollment.~* Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).~* Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.~* Inability to comply with study requirements.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuromodulation for Children With Cystic Fibrosis Experiencing Chronic Abdominal Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking and willing to consent and follow the study protocol~* Children with CF aged 11-17 years at the time of enrollment. All races, ethnic groups and both sexes will be included. Patient turning 18 years after enrollment in the study will continue in study and complete remaining study visits.~* Minimum of 2 days of abdominal pain/week for a duration of two months or greater prior to starting the study~* Average weekly abdominal pain score of at least 3 for the previous 2 weeks prior to entering the study (on a 0-10-point rating scale).~* Abdominal pain is not explained by any major organic etiology and comprehensive work up failed to identify any single cause for patients' symptoms~EXCLUSION CRITERIA:~* Patients age of 18 years and over, or less than 11 years at the time of enrollment~* Patients who cannot provide informed consent or do not speak English~* Patients with abdominal pain that can be explained clinically by other GI diagnoses other than CF per study doctor's judgement~* History of cranial nerve or major abdominal surgeries in last 6 months~* Patients with underlying neurologic conditions, including history of ongoing seizures or traumatic brain injury within last 6 months~* Patients with dermatologic conditions affecting the ears (i.e. psoriasis), or with cuts or abrasions to the external ear that would interfere with electrode placement~* Patients with hemophilia or other bleeding disorders~* Patients with any implanted electromagnetic device~* Inability to comply with study protocol and follow up, per study doctor's judgement.~* Pregnant females, females who are breastfeeding or who believe they may wish to become pregnant during the course of the study~* Males and females of reproductive potential who are unwilling to use effective measures (chosen in consultation with their health care provider) to avoid becoming pregnant.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Patient open label intervention arm (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female aged ≥ 25 years~2. Patient or substitute decision maker willing and able to give informed consent~3. Incident to dialysis defined as within a 12-week window from the first dialysis treatment (1 week prior to, to 11 weeks after). Patients on all forms of dialysis except CRRT (including peritoneal dialysis, home hemodialysis, in-centre intermittent hemodialysis and nocturnal dialysis) will be eligible. Patients returning to dialysis after transplant graft loss will be eligible.~Exclusion Criteria:~1. Past history of allergy to, or intolerance of, escitalopram~2. Known severe hepatic dysfunction~3. Recent history of active bleeding within the past 3 months (e.g. gastrointestinal bleeding requiring hospitalization) or known bleeding disorder~4. Current use of class I anti-arrhythmic medications; SSRI or SNRI antidepressants; pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine or methyldopa, omeprazole; tri-cyclic and tetra-cyclic anti-depressants, neuroleptics or anti-convulsants, triptans, tramadol, linezolid, tryptophan, and St. John's Wort; but not gabapentin~5. Past treatment failure for depression with escitalopram or with ≥ 2 antidepressant treatments of at least 6 weeks duration each~6. Initiation of psychotherapy for depression in the 3 months prior to study entry~7. Alcohol or substance abuse or dependence that requires acute detoxification at study entry~8. Present or past psychosis or bipolar disorder, schizophrenia or any other psychotic disorder documented in medical records~9. Suicidal ideation defined as the patient is at significant risk of suicide on the Columbia Suicide Scale71 or has attempted suicide within 6 months prior to the Screening Visit~10. Clinically-identified major depressive disorder that, in the opinion of the clinical team, requires treatment~11. Pregnancy, lactation and women of childbearing potential not using adequate contraception~12. Abnormal QTc at baseline: QTcF interval \>600 ms (based on the Fredericia correction where QTcF = QT/RR0.33)66~13. Lactose intolerance (as placebo contains lactose)~14. Known uncontrolled glaucoma~15. Patients requiring treatment with continuous renal replacement therapy (CRRT)~16. Documented history of brain tumour

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Flow Cytometry Analysis of the Reactive Oxygen Species in Immature Granulocytes in Septic Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~• Adult patients hospitalized in ICU or ED for acute sepsis~Exclusion Criteria:~* Immunosupressed patients~* Active cancer~* HIV~* Hematological or inflammatory diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evaluated (Type: None): An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Patients With Positive Urine Cocaine Metabolites Undergoing General Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists rating of 1-111~* Positive cocaine metabolite~* urgent surgery for acute abdomen, orthopedic trauma, maxillary-facial trauma~Exclusion Criteria:~* Failure to provide consent~* females who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Systemic Lupus meeting the ACR (American College of Rheumatology) criteria, progressive either SLEDAI activity score ≥ 4, despite a corticosteroid therapy ≥ 10 mg / d associated with hydroxychloroquine (in the absence of contraindication or intolerance) and / or an immunosuppressive treatment at a stable dose,~* Insured,~* Availability for hospitalization required by the protocol (conventional and daily hospitalizations).~Exclusion Criteria:~* Inability to give their signed informed consent form,~* Performans status \> 2~* QTcorrected space before treatment \> 0.45 seconds~* Hemoglobin less than 11g/dL~* Neutrophils rate below 1 200 / mm3~* Platelets rate below 100 Giga / mm3~* Previous history of arrhythmia or heart rhythm disorder or other rhythm trouble by referring cardiologist~* Heart disorder (progressive pericarditis, valvular disease, ...) according to cardiologist~* Family previous history of arrhythmias~* Taking drugs that potentially prolong the QT~* Hypersensitivity to the active substance of Trisenox® or any of the excipients~* Serum potassium ≤ 4 milliequivalent / L~* Magnesemia ≤ 1,8 mg / dl~* Increase corticosteroids beyond 20 mg / day within 15 days before inclusion~* Immunosuppressive treatments, thalidomide introduced within the last 3 months~* Biotherapy (rituximab, belimumab, ...) introduced within 6 months prior to inclusion~* Pregnancy or lactation~* For women of childbearing age, men and their partner : unless effective contraception for the duration of participation in the study that is 7 months~* Creatinine clearance \<50 ml / min,~* Hepatocellular insufficiency (TP \<50%), and / or AST (aspartate aminotransferase) / ALT (alanine aminotransferase) / ALP (alkaline phosphatase) \> 2N~* HBsAg positive, DNA detectable HbS~* Infection with HIV, HBV (hepatitis B virus) or HCV (hepatitis C virus)~* Renal or progressive central neurological impairment with possible alternative therapeutic (to be discussed with the principal investigator and scientific board meeting)~* Peripheral neuropathy~* Unweaned alcoholism~* Minor~* Patients older than 65 years~* Patient having been professionally exposed to arsenic (cleaning electronic circuits for example)~* Guardianship patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arsenic trioxide (Type: EXPERIMENTAL): Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LymphoPilot Test for Limb Lymphedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, 18 years and older~* Patients with unilateral secondary upper or lower limb lymphedema.~Exclusion Criteria:~* Active cellulitis/infection~* Lymphedema associated with active cancer requiring chemotherapy or radiotherapy~* Motor and sensitive neurological deficiency~* Post-operative edema (i.e. acute edema following breast cancer related surgery)~* Any contraindication to surgery or to loco-regional or general anesthesia~* Patient participating in any other clinical study~* Patient unable to provide informed consent~* Patient with pacemaker~* Pathologies associated with an overload of the cardiac system~* Poor wound healing~* Pregnancy or breastfeeding~* Known intolerance to implantable devices~* Known allergies to silicone~* Patient needing magnetic therapy~* Any other condition that according to the principal investigator makes the patient unsuitable for the participation in the trial~* Patient refusing to receive information about incidental findings on her health status discovered during the clinical investigation~* L-Dex score lower than 6.5 at screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LymphoPilot (Type: EXPERIMENTAL): Patient will be implanted with the medical device under investigation, LymphoPilot, through a surgical procedure performed in loco-regional or general anesthesia. Lymphedema outcomes will be monitored for 8 weeks after implantation and compared to baseline values before device implantation. Safety data will be collected throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treating Refractory Schizophrenia With rTMS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients enrolling to the study:~  * must be stable on their medications at the start of their enrollment in the study and throughout the duration of the study;~ * must have no history of substance use of substance-dependence issues over at least the past six months;~ * must be able to and have the capacity to provide consent;~ * and if older patient, he/she must be able to participate without a safeguard to be present.~Exclusion Criteria:~* Patients excluded from the study are:~  * Patients with typical clinical considerations that exclude them from treatment with TMS (i.e., patients who have had head injuries, patients with metal implants, patients with a history of seizures, patients with elevated risk of seizures, patients who are taking medications that may interfere with TMS or potentiate the related side effects, etc.).~ * Patients who have had changes in their medications (i.e., patients must be stable on their medications throughout their participation in the study).~ * Patients with history of substance abuse or substance-dependence anytime over the past six months.~ * Patients who are unable (i.e., do not have the capacity) to consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
- Placebo (Type: EXPERIMENTAL): Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for abdominal-based autologous breast reconstruction (DIEP, MS-TRAM, or TRAM).~* At least 18 years of age.~* Female.~* Able to understand and willing to sign a written informed consent document.~Exclusion Criteria:~* Cognitive impairment.~* History of abdominal surgery precluding free flap donor site.~* Allergy or intolerance to bupivacaine or amide anesthetics.~* Significant preoperative chronic pain (requiring daily narcotics) or neuropathic pain (requiring daily use of pregabalin or gabapentin) within the previous 3 months.~* Pregnant or breastfeeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Bupivicaine (Type: ACTIVE_COMPARATOR): -TAP block of 30 cc of 0.25% bupivicaine
- Group 2: Liposomal bupivacaine (Type: EXPERIMENTAL): -TAP block of 266 mg/30 cc liposomal bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Walking Impairment Questionnaire in PAD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* informed consent signed, french language fluent patients~Exclusion Criteria:~* rejection of the questionnaire

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- claudicants (Type: None): patients referred for a treadmill test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues